Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 6;7(11):1350–1373. doi: 10.1038/s41551-023-01061-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a, Schematic of the experimental protocol to analyse the effects of PHM on the sensitivity to angiotensin II (ang. II) or valsartan injected into the unilateral RVLM. Angiotensin II (100 pmol) was injected into the unilateral RVLM of WKY rats and SHRSPs that were either left sedentary (daily anaesthesia) or treated with PHM (30 min per day, 28 days), with their blood pressure monitored under urethane anaesthesia. Injection of valsartan (100 pmol) into the RVLM was conducted at least 2 h after the injection of angiotensin II. b, Representative trajectories of blood pressure (top) and MAP (bottom). The arrows point to the time of the initiation of RVLM injection of angiotensin II. c, Quantification of the change in MAP caused by injection of angiotensin II (P = 0.9876 (column 1 versus 2), P = 0.0003 (column 3 versus 4)). n = 5 (each group of WKY), n = 7 (SHRSP, −PHM) and n = 8 (SHRSP, +PHM) rats. d,e, The effects of injection of valsartan (100 pmol) in the RVLM were examined as described in b and c (the change in blood pressure and MAP (d) and the MAP trajectory (e)) (P = 0.9953 (column 1 versus 2), P = 0.0099 (column 3 versus 4) (e)). n = 3 (WKY, −PHM), n = 5 (WKY, +PHM) and n = 4 (each group of SHRSPs) rats. Data are mean ± s.e.m. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc multiple-comparison test; **P < 0.01, ***P < 0.001. For b and d, scale bars, 1 min (horizontal) and 50 mm Hg (vertical).

Source data